Biochemical Recurrence

When to Start ADT With A PSA Only Recurrence

Deferred hormone therapy (ADT) for in relapsing M0 (negative scans) prostate cancer patients is associated with prolonged overall survival (OS) measured from the time of local treatment, comparable to OS with salvage ADT in the contemporary experience.

Time to PSA Recurrence Is A Surrogate Endpoint for Prostate Cancer Survival

In an analysis of the NRG Oncology clinical trial NRG-RTOG 9202 it was shown that the interval of time to biochemical reoccurrence (PSA only or BCR), or the time it takes for previously treated prostate cancer to return as indicated by a prostate-specific antigen (PSA) rise, could be used as a surrogate endpoint for survival for men with locally advanced prostate cancer. 

PSA Doubling Time And Proximal PSA Predict Metastasis-Free Survival In Men With Biochemically Recurrent Prostate Cancer After A Radical Prostatectomy

PSA doubling time and the proximal PSA value are excellent predictors of the timing to the formation of metastatic prostate cancer in men who experience a biochemical recurrence (PSA only after surgery).